AR090739A1 - Nicotinamidas 6-amino sustituidas con un grupo que contiene oh como moduladores de kcnq2/3 - Google Patents

Nicotinamidas 6-amino sustituidas con un grupo que contiene oh como moduladores de kcnq2/3

Info

Publication number
AR090739A1
AR090739A1 ARP130101283A ARP130101283A AR090739A1 AR 090739 A1 AR090739 A1 AR 090739A1 AR P130101283 A ARP130101283 A AR P130101283A AR P130101283 A ARP130101283 A AR P130101283A AR 090739 A1 AR090739 A1 AR 090739A1
Authority
AR
Argentina
Prior art keywords
residue
aliphatic residue
aliphatic
mono
polysubstituted
Prior art date
Application number
ARP130101283A
Other languages
English (en)
Spanish (es)
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of AR090739A1 publication Critical patent/AR090739A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355Non-condensed oxazines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
ARP130101283A 2012-04-18 2013-04-18 Nicotinamidas 6-amino sustituidas con un grupo que contiene oh como moduladores de kcnq2/3 AR090739A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12002709 2012-04-18

Publications (1)

Publication Number Publication Date
AR090739A1 true AR090739A1 (es) 2014-12-03

Family

ID=48227140

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130101283A AR090739A1 (es) 2012-04-18 2013-04-18 Nicotinamidas 6-amino sustituidas con un grupo que contiene oh como moduladores de kcnq2/3

Country Status (21)

Country Link
EP (1) EP2888233B1 (https=)
JP (1) JP6033403B2 (https=)
CN (1) CN104428287A (https=)
AR (1) AR090739A1 (https=)
AU (1) AU2013248637A1 (https=)
BR (1) BR112014025840A2 (https=)
CA (1) CA2870573A1 (https=)
CY (1) CY1118255T1 (https=)
DK (1) DK2888233T3 (https=)
EA (1) EA201401142A1 (https=)
ES (1) ES2605947T3 (https=)
HK (1) HK1210173A1 (https=)
HR (1) HRP20161424T1 (https=)
HU (1) HUE030859T2 (https=)
IL (1) IL235030A0 (https=)
LT (1) LT2888233T (https=)
MX (1) MX2014012494A (https=)
PT (1) PT2888233T (https=)
RS (1) RS55466B1 (https=)
SI (1) SI2888233T1 (https=)
WO (1) WO2013156154A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201809184VA (en) * 2016-04-22 2018-11-29 Ono Pharmaceutical Co Crystal polymorphism of kcnq2-5 channel activator
JP7262468B2 (ja) * 2017-12-29 2023-04-21 スリーエム イノベイティブ プロパティズ カンパニー 熱硬化性2剤型加工用接着剤組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2230392A1 (de) 1972-06-22 1974-01-31 Cassella Farbwerke Mainkur Ag Substituierte pyridinverbindungen und verfahren zu ihrer herstellung
DE2513949A1 (de) 1975-03-29 1976-10-07 Bayer Ag Azofarbstoffe
CA2438868A1 (en) 2001-02-20 2002-09-19 Valentin K. Gribkoff Modulators of kcnq potassium channels and use thereof in treating migraine and mechanistically related diseases
US20020183335A1 (en) * 2001-02-20 2002-12-05 Piyasena Hewawasam 2, 4-disubstituted pyrimidine-5-carboxamide derivatives as KCNQ potassium channel modulators
EP2086935A1 (de) * 2006-10-16 2009-08-12 Grünenthal GmbH Substituierte sulfonamid-derivate als bradykinin 1 rezeptor modulatoren
DE102006049452A1 (de) 2006-10-17 2008-05-08 Grünenthal GmbH Substituierte Tetrahydropyrolopiperazin-Verbindungen und deren Verwendung in Arzneimitteln
HRP20120822T1 (hr) 2008-10-24 2012-11-30 Grünenthal GmbH Supstituirani 4,5,6,7-tetrahidrotienopiridini kao kcnq2/3 modulatori za lijeäśenje boli, epilepsije i urinarne inkontinencije
TWI475020B (zh) 2009-03-12 2015-03-01 The substituted nicotine amide as a KCNQ2 / 3 modifier
PE20140199A1 (es) * 2010-10-20 2014-02-16 Gruenenthal Chemie 6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3

Also Published As

Publication number Publication date
ES2605947T3 (es) 2017-03-17
EP2888233A1 (en) 2015-07-01
DK2888233T3 (en) 2017-01-09
HUE030859T2 (en) 2017-06-28
MX2014012494A (es) 2015-01-15
JP6033403B2 (ja) 2016-11-30
SI2888233T1 (sl) 2016-12-30
RS55466B1 (sr) 2017-04-28
CY1118255T1 (el) 2017-06-28
CA2870573A1 (en) 2013-10-24
BR112014025840A2 (pt) 2017-07-18
EA201401142A1 (ru) 2015-03-31
LT2888233T (lt) 2017-01-10
EP2888233B1 (en) 2016-09-28
CN104428287A (zh) 2015-03-18
PT2888233T (pt) 2017-01-04
JP2015514728A (ja) 2015-05-21
AU2013248637A1 (en) 2014-12-04
HK1210173A1 (en) 2016-04-15
WO2013156154A1 (en) 2013-10-24
HRP20161424T1 (hr) 2016-12-16
IL235030A0 (en) 2014-12-31

Similar Documents

Publication Publication Date Title
AR097325A1 (es) Pirroles anillados
AR114971A1 (es) Compuestos de purinona y su uso en el tratamiento del cáncer
AR087301A1 (es) Derivados de carboxamida y urea que contienen pirazol heteroaromatico sustituido como ligandos del receptor de vanilloide
AR107154A1 (es) Estimuladores de guanilato ciclasa soluble
AR092279A1 (es) Pirrol carboxamidas fluorometilo sustituidas
CU20150014A7 (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
RU2014129742A (ru) Производные бензолсульфонамида в качестве модуляторов rorc
AR102389A1 (es) Profármacos de carbidopa y l-dopa y métodos de uso de los mismos, kit
EA200971115A1 (ru) Новые ингибиторы обратной транскриптазы вич
AR069490A1 (es) Agonistas de los receptores de glucocorticoides
CY1118478T1 (el) Παραγωγα τυπου αζαϊνδαζολιου ή διαζαϊνδαζολιου για τη θεραπεια του πονου
AR058388A1 (es) DERIVADOS DE COMPUESTOS AROMATICOS SUSTITUIDOS uTILES PARA TRASTORNOS RESPIRATORIOS , COMPOSICIONES FARMACÉUTICAS Y PROCESOS PARA SU PREPARACIoN
AR083477A1 (es) 6-aminonicotinamidas sustituidas utiles para el tratamiento del dolor y composiciones farmaceuticas que las contienen
AR107828A1 (es) 2-amino-n-[7-metoxi-2,3-dihidroimidazo-[1,2-c]quinazolin-5-il]pirimidin-5-carboxamidas como inhibidor de pi3k
AR087302A1 (es) Derivados aza heterociclicos sustituidos
AR094812A1 (es) Derivado de piridina monocíclico como inhibidor del fgfr
AR094735A1 (es) Benzamidas sustituidas con actividad hacia receptores ep4
EA201401082A1 (ru) Фармацевтические препараты, содержащие антагонисты ccr3
AR122096A2 (es) Compuestos profármacos de creatina y composiciones que los comprenden
AR100715A1 (es) Derivados de alquilo de compuestos 1-oxa-4,9-diazaespiro undeceno que tienen actividad multimodal contra el dolor
AR106296A1 (es) Tetrahidropiranilsulfonas sustituidas con pirazolilo
AR082732A1 (es) 2-oxiquinolina-3-carboxamidas sustituidas como moduladores de kcnq2/3
AR061973A1 (es) Compuesto de 2-arilindol sustituido en la posicion 5, composicion farmaceutica que lo comprende, compuestos intermedios y procedimiento para la preparacion de los mismos
EA202190285A1 (ru) Производные аминопиридина и их применение в качестве селективных ингибиторов alk–2
AR082734A1 (es) Quinolino-3-carboxamidas sustituidas como moduladores de kcnq2/3

Legal Events

Date Code Title Description
FB Suspension of granting procedure